Compositions and methods for mucosal vaccination against SARS-CoV-2

Patent metadata

Field	Value
Publication number	US-12297232-B2
Application number	US-202117187214-A
Country	US
Kind code	B2
Filing date	Feb 26, 2021
Priority date	Feb 26, 2020
Publication date	May 13, 2025
Grant date	May 13, 2025

Abstract

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.

First claim

We claim:

1. A peptide comprising
a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn);
a full length soluble SARS-COV-2 spike(S) protein; and
a trimerization domain.

2. The peptide of claim 1 , wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises a mutation in the cysteine residues responsible for dimer formation.

3. The peptide of claim 2 , wherein the cysteine residues are at position 11 and 14 of SEQ ID NO:7.

4. The peptide of claim 2 , wherein the mutation is a cysteine to serine substitution.

5. The peptide of claim 1 , wherein C1q motif has been mutated such that it renders the fragment non-lytic.

6. The peptide of claim 1 , wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises a CH2 domain and a CH3 domain.

7. The peptide of claim 6 , wherein the monomeric Fc fragment of an immunoglobulin recognized by a FcRn comprises one or more mutations in the CH2 domain, wherein the one or more mutations in the CH2 domain ablate C1q binding to the monomeric Fc fragment.

8. The peptide of claim 1 , wherein the trimerization domain is a T4 fibritin trimerization domain.

9. The peptide of claim 1 , wherein the monomeric Fc fragment is conjugated to the carboxy terminal end of the full length soluble SARS-COV-2 spike protein.

10. A peptide complex comprising three peptides, wherein each of the peptides is the peptide of claim 1 .

11. A composition comprising the peptide of claim 1 .

12. A composition comprising the peptide complex of claim 10 .

13. A method for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of the composition of claim 11 .

14. A method for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of a composition comprising a peptide complex, wherein the peptide complex comprises three peptides forming a trimer, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; a full length soluble SARS-COV-2 S protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.

15. A method of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to the subject an effective amount of the composition of claim 11 .

16. A method of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to the subject an effective amount of a composition comprising a peptide complex, wherein the peptide complex comprises three peptides forming a trimer, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; a full length soluble SARS-COV-2 S protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.

Assignees

• Univ Maryland

Inventors

• Zhu Xiaoping
• Li Weizhong
• Wang Tao

Classifications

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• A61K2039/543

  intranasal · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K2317/526

  CH3 domain · CPC title